Literature DB >> 17342152

Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review.

Ansgar Gerhardus1, Henriette Schleberger, Brigitte Schlegelberger, Dorothea Gadzicki.   

Abstract

As sequence analysis for BRCA1 and BRCA2 mutations is both time- and cost-intensive, current strategies often include scanning techniques to identify fragments containing genetic sequence alterations. However, a systematic assessment of the diagnostic accuracy has been lacking so far. Here, we report on a systematic review to assess the internal and external validity of current scanning techniques. Inclusion criteria were: controlled design, investigators blinded, and tests suitable as a scanning tool for the whole genes BRCA1 and BRCA2. Outcome parameters were sensitivity, specificity, and positive and negative predictive values compared to direct sequencing. Out of 3816 publications, 10 studies reporting on 12 methods met our inclusion criteria. The internal and external validity of most of these studies was limited. Sensitivities were reported to be 100% for enzymatic mutation detection (EMD), multiple-dye cleavase fragment length polymorphism (MD-CFLP), fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE), RNA-based sequencing, restriction endonuclease fingerprinting-single strand conformation polymorphism (REF-SSCP), stop codon (SC) assay, and denaturing high-performance liquid chromatography (DHPLC). Sensitivity was 50-96% for SSCP, 88-91% for two-dimensional gene scanning (TDGS), 76% for conformation-sensitive gel electrophoresis (CSGE), 75% for protein truncation test (PTT), and 58% for micronucleus test (MNT). Specificities close to 100% were reported, except for MNT. PTT and SC assay are only able to detect truncating mutations. Most studies were designed to introduce new experimental approaches or modifications of established methods and require further evaluation. F-CSGE, REF-SSCP, RNA-based sequencing, EMD, and MD-CFLP will need further evaluation before their use in a routine setting can be considered. SSCP, MNT, PTT, CSGE, and TDGS cannot be recommended because of their low sensitivity. DHPLC outperforms all other methods studied. However, none of the four studies evaluating DHPLC was performed on BRCA2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342152     DOI: 10.1038/sj.ejhg.5201806

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  23 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

3.  Two novel frameshift mutations in BRCA2 gene detected by next generation sequencing in a survey of Spanish patients of breast cancer.

Authors:  I Hernan; B Mañé; E Borràs; M de Sousa Dias; G Llort; C Yagüe; M J Gamundi; À Arcusa; M Carballo
Journal:  Clin Transl Oncol       Date:  2015-01-14       Impact factor: 3.405

4.  A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer.

Authors:  Jing Ma; Jichun Yang; Wenjing Jian; Xianming Wang; Deyong Xiao; Wenjun Xia; Likuan Xiong; Duan Ma
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-05       Impact factor: 4.553

Review 5.  BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Authors:  Edgar S Diaz-Cruz; Marina C Cabrera; Rebecca Nakles; Beth H Rutstein; Priscilla A Furth
Journal:  Breast Dis       Date:  2010

6.  BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing.

Authors:  Kumaravel Somasundaram
Journal:  Indian J Surg Oncol       Date:  2011-03-11

Review 7.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

Review 8.  Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

Authors:  Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell
Journal:  Breast Cancer Res       Date:  2008-11-28       Impact factor: 6.466

9.  c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.

Authors:  Beata S Lipska; Elzbieta Drozynska; Paola Scaruffi; Gian Paolo Tonini; Ewa Izycka-Swieszewska; Szymon Zietkiewicz; Anna Balcerska; Danuta Perek; Alicja Chybicka; Wojciech Biernat; Janusz Limon
Journal:  BMC Cancer       Date:  2009-12-13       Impact factor: 4.430

Review 10.  Recent omics technologies and their emerging applications for personalised medicine.

Authors:  Dong-Hyuk Kim; Young-Sook Kim; Nam-Il Son; Chan-Koo Kang; Ah-Ram Kim
Journal:  IET Syst Biol       Date:  2017-06       Impact factor: 1.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.